Suppr超能文献

DNA 修复机制失衡与甲状腺乳头状癌中 BRAF 突变和肿瘤侵袭性相关。

Imbalance in DNA repair machinery is associated with BRAF mutation and tumor aggressiveness in papillary thyroid carcinoma.

机构信息

Laboratory of Genetic Toxicology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, Brazil.

Laboratory of Genetic Toxicology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Rio Grande do Sul, Brazil; Laboratory of Molecular and Cellular Cardiology, Instituto de Cardiologia/Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Rio Grande do Sul, Brazil.

出版信息

Mol Cell Endocrinol. 2018 Sep 5;472:140-148. doi: 10.1016/j.mce.2017.12.004. Epub 2017 Dec 8.

Abstract

The involvement of alterations in MLH1, an essential mismatch repair component, in BRAF mutated papillary thyroid carcinoma (PTC) has been suggested to be associated with features of tumor aggressiveness. Thirty-two PTC and surrounding normal thyroid tissues were evaluated for 11 representative DNA repair genes expression. BRAF mutational status assessment and clinicopathological correlations were evaluated for their gene and protein expression. BRAF PTC is associated with lower levels of XPD and MLH1 gene expression. Decrease in MLH1 and XPD mRNA levels in BRAF PTC (but not their protein products) are associated with predictors of poor patient outcomes. Considering the complete subset of patients, MGMT and XRCC2 genes were shown down and upregulated, respectively, in PTC tissues. Low expression of MGMT gene and weak XRCC2 protein expression were correlated with characteristics of tumor aggressiveness. These results suggest that an imbalance in DNA repair gene expression in PTC is associated with aggressive clinicopathological features and BRAF mutation.

摘要

已有人提出,在 BRAF 突变型甲状腺乳头状癌(PTC)中,关键错配修复成分 MLH1 的改变与肿瘤侵袭性特征有关。评估了 32 例 PTC 和周围正常甲状腺组织中 11 个代表性 DNA 修复基因的表达情况。评估了 BRAF 突变状态以及临床病理相关性,以评估其基因和蛋白表达情况。BRAF PTC 与 XPD 和 MLH1 基因表达水平降低有关。BRAF PTC 中 MLH1 和 XPD mRNA 水平降低(但不是其蛋白产物)与患者预后不良的预测因子有关。考虑到所有患者,MGMT 和 XRCC2 基因在 PTC 组织中分别下调和上调。MGMT 基因表达水平低和 XRCC2 蛋白表达弱与肿瘤侵袭性特征相关。这些结果表明,PTC 中 DNA 修复基因表达失衡与侵袭性临床病理特征和 BRAF 突变有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验